| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5854290 | TAKEDA PHARMS USA | Use of guanfacine in the treatment of behavioral disorders |
Sep, 2015
(8 years ago) | |
|
US5854290 (Pediatric) | TAKEDA PHARMS USA | Use of guanfacine in the treatment of behavioral disorders |
Mar, 2016
(8 years ago) | |
| US6287599 | TAKEDA PHARMS USA | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
Dec, 2020
(3 years ago) | |
|
US6287599 (Pediatric) | TAKEDA PHARMS USA | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
Jun, 2021
(2 years ago) | |
| US6811794 | TAKEDA PHARMS USA | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
Jul, 2022
(1 year, 9 months ago) | |
|
US6811794 (Pediatric) | TAKEDA PHARMS USA | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
Jan, 2023
(1 year, 3 months ago) | |
Intuniv is owned by Takeda Pharms Usa.
Intuniv contains Guanfacine Hydrochloride.
Intuniv has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Intuniv are:
- US5854290
- US5854290*PED
- US6287599
- US6287599*PED
- US6811794
- US6811794*PED
Intuniv was authorised for market use on 02 September, 2009.
Intuniv is available in tablet, extended release;oral dosage forms.
Intuniv can be used as treatment of attention-deficit hyperactivity disorder.
The generics of Intuniv are possible to be released after 04 January, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-154) | Mar 18, 2018 |
| New Dosing Schedule(D-145) | Nov 19, 2017 |
| Pediatric Exclusivity(PED) | May 19, 2018 |
| New Indication(I-635) | Feb 25, 2014 |
| New Product(NP) | Sep 02, 2012 |
Drugs and Companies using GUANFACINE HYDROCHLORIDE ingredient
Market Authorisation Date: 02 September, 2009
Treatment: Treatment of attention-deficit hyperactivity disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
INTUNIV family patents
